9VC Stock Overview
A clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Atai Life Sciences N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.42 |
| 52 Week High | US$2.48 |
| 52 Week Low | US$0.94 |
| Beta | 0.78 |
| 11 Month Change | 22.39% |
| 3 Month Change | 24.97% |
| 1 Year Change | 43.93% |
| 33 Year Change | -85.73% |
| 5 Year Change | n/a |
| Change since IPO | -90.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9VC | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.4% | -5.0% | -1.3% |
| 1Y | 43.9% | -22.0% | 7.4% |
Return vs Industry: 9VC exceeded the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: 9VC exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| 9VC volatility | |
|---|---|
| 9VC Average Weekly Movement | 12.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9VC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9VC's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 83 | Srini Rao | www.atai.life |
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology.
Atai Life Sciences N.V. Fundamentals Summary
| 9VC fundamental statistics | |
|---|---|
| Market cap | €244.93m |
| Earnings (TTM) | -€123.50m |
| Revenue (TTM) | €317.86k |
816.2x
P/S Ratio-2.1x
P/E RatioIs 9VC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9VC income statement (TTM) | |
|---|---|
| Revenue | US$331.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$331.00k |
| Other Expenses | US$128.93m |
| Earnings | -US$128.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.77 |
| Gross Margin | 100.00% |
| Net Profit Margin | -38,852.87% |
| Debt/Equity Ratio | 15.5% |
How did 9VC perform over the long term?
See historical performance and comparison